Moleculin Biotech, Inc. SEC filings MBRX
Moleculin Biotech, Inc. has 838 filings in SEC EDGAR's recent list, going back to Dec 4, 2015. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Aug 24, 2026 | — |
| DEF 14A | Proxy statement | Aug 24, 2026 | Oct 9, 2026 |
| PRE 14A | Preliminary proxy statement | Aug 14, 2026 | Oct 9, 2026 |
| DEF 14A | Proxy statement | Mar 9, 2026 | Apr 15, 2026 |
| PRE 14A | Preliminary proxy statement | Feb 26, 2026 | Apr 15, 2026 |
| DEF 14A | Proxy statement | Jan 2, 2026 | Feb 5, 2026 |
| PRE 14A | Preliminary proxy statement | Dec 19, 2025 | Feb 5, 2026 |
| DEF 14A | Proxy statement | Sep 15, 2025 | Oct 16, 2025 |
| PRE 14A | Preliminary proxy statement | Sep 5, 2025 | Oct 16, 2025 |
| DEFA14A | Additional proxy material | Jul 8, 2025 | — |
| DEF 14A | Proxy statement | Jul 8, 2025 | Aug 18, 2025 |
| PRE 14A | Preliminary proxy statement | Jun 27, 2025 | Aug 18, 2025 |
| PRE 14A | Preliminary proxy statement | May 23, 2025 | May 23, 2025 |
| DEF 14A | Proxy statement | Mar 13, 2025 | Apr 9, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 3, 2025 | Apr 9, 2025 |
| DEFA14A | Additional proxy material | Sep 13, 2024 | — |
| DEF 14A | Proxy statement | Sep 13, 2024 | Oct 24, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 3, 2024 | Oct 24, 2024 |
| DEF 14A | Proxy statement | Jan 16, 2024 | Feb 14, 2024 |
| PRE 14A | Preliminary proxy statement | Jan 5, 2024 | Feb 14, 2024 |
| DEF 14A | Proxy statement | Sep 1, 2023 | Oct 3, 2023 |
| PRE 14A | Preliminary proxy statement | Aug 21, 2023 | Oct 3, 2023 |
| DEFA14A | Additional proxy material | Jun 7, 2023 | — |
| DEFA14A | Additional proxy material | May 30, 2023 | — |
| DEFA14A | Additional proxy material | May 12, 2023 | — |
| DEFA14A | Additional proxy material | Apr 13, 2023 | — |
| DEF 14A | Proxy statement | Apr 13, 2023 | May 25, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2023 | May 25, 2023 |
| DEF 14A | Proxy statement | Apr 14, 2022 | May 26, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2022 | May 26, 2022 |
| DEF 14A | Proxy statement | Mar 31, 2021 | May 26, 2021 |
| DEFA14A | Additional proxy material | May 15, 2020 | — |
| DEFA14A | Additional proxy material | May 8, 2020 | — |
| DEF 14A | Proxy statement | Apr 7, 2020 | Apr 7, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2020 | Mar 27, 2020 |
| DEFA14A | Additional proxy material | May 3, 2019 | — |
| DEF 14A | Proxy statement | Apr 16, 2019 | Apr 16, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2019 | Apr 5, 2019 |
| DEF 14A | Proxy statement | Apr 27, 2018 | Apr 27, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2018 | Apr 13, 2018 |
| DEFA14A | Additional proxy material | May 23, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | May 25, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2017 | Apr 18, 2017 |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1659617
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.